Latest from Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute

Hyung L. Kim, MD, discusses perioperative systemic therapy for patients with kidney cancer.

Howard M. Sandler, MD, discusses the emergence of hypofractionation as a viable treatment approach for patients with prostate cancer.

Stephen J. Freedland, MD, shares his insight on how to counsel patients with prostate cancer on the benefits of leading a healthier life.

Timothy J. Daskivich, MD, discusses the use of High-intensity focused ultrasound and other treatment strategies in the prostate cancer armamentarium.

Amit Gupta, MD, urologic oncologist, Department of Surgery, Cedars-Sinai Medical Center, discusses how the use of immunotherapy agents is altering the role of surgery in bladder cancer and the need for Bacillus Calmette-Guérin (BCG) alternatives.

Edwin M. Posadas, MD, discusses the evolution of prostate cancer therapy, including the earlier use of advanced-stage agents and the potential for immunotherapy in the field.

Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.

Howard M. Sandler, MD, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses hypofractionation in prostate cancer.